NGS in Gallbladder Cancer and Response to Treatment

Summary

Evidence suggests distinct models of molecular and pathologic progression, and a growing body of genetics data points to a heterogeneous collection of underlying mutations in key oncogenes and tumor suppressor genes. Although tumor genetics have been used to tailor individual treatment regimens and guide clinical decision making in other cancers, these principles have not been applied in gallbladder malignancy. Recent clinical trials with targeted therapies seem promising, although the relationships between subsets of patients with positive responses to therapy and tumor genetics remain unexplored.

Eligibility

Inclusion Criteria:

* Treatment naïve patients with histologically proven carcinoma of the gallbladder.

Exclusion Criteria:

* No histological evidence of malignancy
* Pregnant and lactating women

Conditions2

Browse More Trials